| 1 |
Cimier A, Thach S, Lacroix B, Mariat C. [Evaluation of the efficacy and safety of HIVEC intravesical thermochemotherapy with intermediate-risk and high-risk non-muscle-invasive bladder cancer]. Prog Urol 2023:S1166-7087(23)00062-3. [PMID: 36906430 DOI: 10.1016/j.purol.2023.02.007] [Reference Citation Analysis]
|
| 2 |
Anastay V, Baboudjian M, Masson-Lecomte A, Lebacle C, Chamouni A, Irani J, Tillou X, Waeckel T, Monges A, Duperron C, Gravis G, Walz J, Lechevallier E, Pignot G. Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure? Cancers (Basel) 2023;15. [PMID: 36900247 DOI: 10.3390/cancers15051455] [Reference Citation Analysis]
|
| 3 |
Pignot G, Baboudjian M, Lebacle C, Chamouni A, Lechevallier E, Irani J, Tillou X, Waeckel T, Monges A, Doisy L, Walz J, Gravis G, Mourey E, Duperron C, Masson-Lecomte A. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure. World J Urol 2023. [PMID: 36811732 DOI: 10.1007/s00345-023-04332-z] [Reference Citation Analysis]
|
| 4 |
Campodonico F, Mattioli F, Introini C. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. Eur Urol 2023;83:e56-7. [PMID: 36372625 DOI: 10.1016/j.eururo.2022.09.035] [Reference Citation Analysis]
|
| 5 |
Sahoo S, Pandey A, Mandal S, Kumar Das M, Nayak P. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. Eur Urol 2023;83:e47. [PMID: 36404203 DOI: 10.1016/j.eururo.2022.10.027] [Reference Citation Analysis]
|
| 6 |
Tan WS, Kelly JD; HIVEC-II trial team. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. Eur Urol 2023;83:e29-30. [PMID: 36272948 DOI: 10.1016/j.eururo.2022.10.009] [Reference Citation Analysis]
|
